I founded Acorda in 1995 with a specific but challenging mission: to develop therapies that could restore neurological function and improve the lives of people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system.
At the time I founded the company, I was struck by the lack of treatments for these conditions. Over the past 15 years, there has been impressive progress in providing therapeutic options for people with nervous system disorders, particularly MS. We at Acorda are proud of our contributions to this progress, particularly the FDA approval of AMPYRA, to improve walking in people with MS. The majority of people with MS experience impairment of their walking ability, which has a significant impact on their lives.
The approval of AMPYRA is also an important milestone for our company. This success is enabling us to invest in the next generation of therapies for people with neurological disorders, who so desperately need therapeutic alternatives in their lives.
During our first several years, Acorda operated as a "virtual" company which comprised a geographically diverse network of academic scientists, healthcare professionals, patient advocacy groups and business people. Although the company has matured and many of our employees are based at our headquarters in Ardsley, NY, we’ve remained true to our origins as a collaborative enterprise — both within the company and with external partners with whom we share a sense of mission. This unusually high level of teamwork has contributed substantially to our ability to innovate successfully, from product identification to preclinical, clinical and commercial development.
As you browse through Acorda.com and learn more about our company and the Acordans who are working to bring important new therapies to people with nervous system disorders, I hope what stands out is that our sense of commitment to medical innovation and patient benefit is as strong today as it was back in 1995, when we started with two employees and a vision.